BridgeBio Pharma Valuation
| 2CL Stock | EUR 65.04 0.48 0.73% |
At this time, the firm appears to be overvalued. BridgeBio Pharma shows a prevailing Real Value of €52.96 per share. The current price of the firm is €65.04. Our model approximates the value of BridgeBio Pharma from analyzing the firm fundamentals such as Return On Asset of -0.43, shares outstanding of 191.63 M, and Operating Margin of (1.13) % as well as examining its technical indicators and probability of bankruptcy.
Enterprise Value 13.7 B | Enterprise Value Ebitda (9.56) | Price Sales 36.1405 | Enterprise Value Revenue 46.2759 |
Overvalued
Today
Please note that BridgeBio Pharma's price fluctuation is very steady at this time. Calculation of the real value of BridgeBio Pharma is based on 3 months time horizon. Increasing BridgeBio Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the BridgeBio stock is determined by what a typical buyer is willing to pay for full or partial control of BridgeBio Pharma. Since BridgeBio Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BridgeBio Stock. However, BridgeBio Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 65.04 | Real 52.96 | Hype 66.39 | Naive 64.19 |
The real value of BridgeBio Stock, also known as its intrinsic value, is the underlying worth of BridgeBio Pharma Company, which is reflected in its stock price. It is based on BridgeBio Pharma's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of BridgeBio Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of BridgeBio Pharma helps investors to forecast how BridgeBio stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BridgeBio Pharma more accurately as focusing exclusively on BridgeBio Pharma's fundamentals will not take into account other important factors: About BridgeBio Pharma Valuation
The stock valuation mechanism determines BridgeBio Pharma's current worth on a weekly basis. Our valuation model uses a comparative analysis of BridgeBio Pharma. We calculate exposure to BridgeBio Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of BridgeBio Pharma's related companies.BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company was founded in 2015 and is headquartered in Palo Alto, California. BRIDGEBIO PHARMA operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 385 people.
Complementary Tools for BridgeBio Stock analysis
When running BridgeBio Pharma's price analysis, check to measure BridgeBio Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BridgeBio Pharma is operating at the current time. Most of BridgeBio Pharma's value examination focuses on studying past and present price action to predict the probability of BridgeBio Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BridgeBio Pharma's price. Additionally, you may evaluate how the addition of BridgeBio Pharma to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |